Oksana Yu. Lazareva

Oksana Yu. Lazareva

Auto-generated profile, based on publicly available information

Oksana Yu. Lazareva

Ryazan State Medical University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2023 in I.P. Pavlov Russian Medical Biological Herald
Verified
Journal Article
Open access
PDF file
ASAleksandra V. Solov'YEva
Aleksandra V. Solov'YEva
AGArzu Arifovna Gurbanova
Arzu Arifovna Gurbanova
IMIvan A. Maksimtsev
Ivan A. Maksimtsev
OLOksana Yu. Lazareva
Oksana Yu. Lazareva
EMElena A. Maksimtseva
Elena A. Maksimtseva
INTRODUCTION: Myocardial bridging (MB) is considered a benign pathology, however, its existence is often associated with angina pectoris, myocardial infarction, ventricular tachycardia and sudden cardiac death. The clinical significance of MB is determined by the dynamic stenosis of the coronary artery, which depends on the rate and strength of heart contractions and is poorly visualized by instrumental methods, which impairs timely diagnosis and early administration of the adequate treatment. A clinical case of a combined damage to the coronary bed in a 58-year-old patient is presented: MB of the anterior interventricular artery (AIVA) causing dynamically significant narrowing of the tunnel artery and hemodynamically insignificant atherosclerotic lesion of the coronary arteries. MB was typically located in the mid-segment of the AIVA. The diagnosis of the anomaly of the coronary bed was established after coronary angiography: MB of AIVA led to stenosis of the tunnel segment to 80% and was the cause of angina attacks. Stenting of the AIVA with a drug-coated stent was performed. The effectiveness of the stenting can be referred to a peculiar feature of this case, since in the treatment of this pathology the preference is given to myotomy and coronary artery bypass grafting as more effective methods. The follow-up period was 7.5 years; after stenting of the tunnel segment of the AIVA the anginal attacks did not recur. CONCLUSION: The described clinical case demonstrates the role of MB in the development of myocardial ischemia. With timely diagnosis of the coronary blood flow disorders, successful revascularization and adequate pharmacotherapy in accordance with the current clinical recommendations, the prognosis is good.

16 April 2025 in I.P. Pavlov Russian Medical Biological Herald
Verified
Journal Article
Open access
PDF file
OUOleg M. Uryas’yEv
Oleg M. Uryas’yEv
OLOksana Yu. Lazareva
Oksana Yu. Lazareva
ASAnton V. Shakhanov
Anton V. Shakhanov
SBSvetlana V. Berstneva
Svetlana V. Berstneva
VLVadim A. Lunyakov
Vadim A. Lunyakov
АААлексеенкова Ксения Александровна
Алексеенкова Ксения Александровна
INTRODUCTION: Dermatomyositis is a rare autoimmune disease. Its development is often associated with malignant solid tumors. Due to the polymorphism of clinical manifestations and low awareness of the primary care physicians of this disease, dermatomyositis remains undiagnosed for a long time, which leads to a late start of treatment. Untimely start of treatment is associated with a poor prognosis for this group of patients. Factors of poor prognosis include the development and progression of dysphagia and also refractoriness to the standard therapy with systemic glucocorticoids (sGC) and immunosuppressants, when it becomes necessary to use alternative methods of treatment, including intravenous immunoglobulin (IVIG). AIM: Demonstration of a clinical case of dermatomyositis resistant to high-dose sGC and methotrexate therapy, that required high-dose IVIG therapy. A clinical case of dermatomyositis in a female patient S., 56 years old, with cutaneous syndrome and muscle weakness, dysphagia and dysphonia is presented. On treatment with prednisolone 1 mg/kg a day orally, methotrexate 15 mg a week subcutaneously, clinical and laboratory dynamics was insignificant, poor tolerance to methotrexate did not permit to increase the dose. Taking into account progressing dysphagia, the medical commission took a decision about high-dose IVIG treatment at a dose 1g/kg once. After four weeks of therapy, clear positive clinical and laboratory dynamics was noted. CONCLUSION: The described clinical case demonstrated the effectiveness and safety of IVIG for treatment of refractory dermatomyositis with insufficient effectiveness of the previous standard therapy with sGC and immune depressants.